North American Spine Society Annual Meeting
North American Spine Society Annual Meeting
August 05, 2014
1 min read

Most patients satisfied after PRP therapy for internal disc disruption

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ORLANDO, Fla. — Platelet-rich plasma injection appeared to be a promising therapy for patients who exhibited intradiscal back pain, according to study findings presented here.

“Intradiscal PRP [platelet-rich plasma] is readily available and something we can use right now. It is a safe and effective treatment for IDD [internal disc disruption],” Gregory Lutz, MD, said at the International Spine Intervention Society Annual Meeting.

In the literature, IDD is described as a syndrome of low back pain that arises from an intervertebral disc after a trauma.

 Lutz, who is the Physiatrist-in-Chief Emeritus for Hospital for Special Surgery in New York, and colleagues conducted a double-blind study which included 42 patients with IDD. The patients were placed either in a control group of 26 patients who received a contrast agent or in an active group of 16 patients who received intradiscal PRP therapy. Patients were allowed to crossover to another group at 8 weeks. Their mean age was 41 years; most of them were men.

Patients reported their satisfaction with treatment with the North American Spine Society survey.

During his presentation Lutz said results at the 8-week follow-up showed 58.3% of patients who received PRP therapy were satisfied with the treatment. By comparison, 13.3% of patients in the control group were satisfied with their treatment.

Additional studies of PRP therapy for individuals with IDD are underway, Lutz said. – by Robert Linnehan


Lutz G. Intradiscal PRP study and MRI predictors of outcome. Presented at: International Spine Intervention Society Annual Meeting; July 30-Aug. 3, 2014; Orlando, Fla.

Disclosure: Lutz is a co-founder, director, and has stock in Orthobond Corp. He is a consultant and has options in Biorestorative Therapies. He has an unrestricted research grant from Harvest Corp.